Invivyd (NASDAQ:IVVD) Insider Julie Green Sells 22,355 Shares

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 22,355 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $16,095.60. Following the sale, the insider directly owned 187,362 shares in the company, valued at approximately $134,900.64. The trade was a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Tuesday, August 18th, Julie Green sold 18,425 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total value of $15,477.00.

Invivyd Price Performance

Shares of NASDAQ:IVVD opened at $0.87 on Wednesday. The firm has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07. The business’s 50 day moving average price is $0.77 and its 200-day moving average price is $1.23.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. On average, sell-side analysts expect that Invivyd, Inc. will post -0.52 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on IVVD shares. BTIG Research restated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Invivyd currently has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Trading of Invivyd

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC purchased a new stake in Invivyd in the second quarter valued at approximately $30,048,000. Janus Henderson Group PLC raised its position in Invivyd by 1.7% during the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock worth $42,857,000 after buying an additional 551,188 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in Invivyd in the fourth quarter valued at about $53,809,000. BVF Inc. IL acquired a new stake in shares of Invivyd in the 4th quarter valued at approximately $48,227,000. Finally, RA Capital Management L.P. acquired a new stake in Invivyd in the third quarter valued at $18,831,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.